Yongin, South Korea

Kwang Ok Lee

This inventor holds 6 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Hanmi Science Co., Ltd., Bukwang Pharmaceutical Co., Ltd., Hanmi Pharm. Co., Ltd.. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kwang Ok Lee. Retrieved from https://idiyas.com/inventor/kwang-ok-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 6.8

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Seoul, KR (2000)
  • Yongin-si, KR (2015 - 2017)
  • Gyeonggi-Do, KR (2022)

Company Filing History:


Years Active: 2000-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations of Kwang Ok Lee in Fused Pyrimidine Derivatives

Introduction

Kwang Ok Lee, an accomplished inventor based in Yongin-si, South Korea, has made significant contributions to the field of pharmaceutical sciences. With a total of four patents to his name, he continues to drive innovation aimed at addressing serious health challenges. His work primarily focuses on the development of fused pyrimidine derivatives aimed at inhibiting tyrosine kinase activity, which plays a critical role in various diseases.

Latest Patents

Among his notable inventions, Kwang Ok Lee has been granted patents for novel fused pyrimidine derivatives that possess inhibitory activity for tyrosine kinases. These innovations are instrumental in formulating pharmaceutical compositions intended for the prevention and treatment of cancers, tumors, inflammatory diseases, autoimmune diseases, and immunologically mediated conditions. This dual patent reinforces the potential impact of his work in modern medicine.

Career Highlights

Kwang Ok Lee has enjoyed a reputable career, having worked with prominent companies such as Hanmi Science Co., Ltd. and Hanmi Pharm. Co., Ltd. His affiliations with these organizations underscore his commitment to research and development in the pharmaceutical industry. His contributions have been vital in advancing the understanding and treatment of critical health issues.

Collaborations

Throughout his career, Kwang Ok Lee has collaborated with esteemed colleagues, including Tae Hee Ha and Mi Young Cha. These partnerships have fostered a productive environment for innovation and have contributed to his successful patent applications, showcasing the collaborative nature of scientific advancement.

Conclusion

Kwang Ok Lee's work exemplifies the spirit of innovation in the pharmaceutical sector. His innovative fused pyrimidine derivatives are not only groundbreaking but also pivotal in the fight against various debilitating diseases. As he continues to build on his accomplishments, his contributions will undoubtedly play a significant role in shaping future medical therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…